A phase I study of BKM120, a novel oral selective phosphatidylinositol-3-kinase (PI3K) inhibitor, in combination with fulvestrant in postmenopausal women with estrogen receptor positive metastatic breast cancer.
Gayathri Nagaraj
No relevant relationships to disclose
Cynthia X. Ma
No relevant relationships to disclose
Jingqin Luo
No relevant relationships to disclose
Matthew J. Ellis
Consultant or Advisory Role - Novartis